Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

A Survey of Genome Editing Activity for 16 Cas12a Orthologs.

Zetsche B, Strecker J, Abudayyeh OO, Gootenberg JS, Scott DA, Zhang F.

Keio J Med. 2019 Nov 14. doi: 10.2302/kjm.2019-0009-OA. [Epub ahead of print]

2.

Programmable Inhibition and Detection of RNA Viruses Using Cas13.

Freije CA, Myhrvold C, Boehm CK, Lin AE, Welch NL, Carter A, Metsky HC, Luo CY, Abudayyeh OO, Gootenberg JS, Yozwiak NL, Zhang F, Sabeti PC.

Mol Cell. 2019 Dec 5;76(5):826-837.e11. doi: 10.1016/j.molcel.2019.09.013. Epub 2019 Oct 10.

3.

SHERLOCK: nucleic acid detection with CRISPR nucleases.

Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F.

Nat Protoc. 2019 Oct;14(10):2986-3012. doi: 10.1038/s41596-019-0210-2. Epub 2019 Sep 23.

PMID:
31548639
4.

CRISPR Tools for Systematic Studies of RNA Regulation.

Engreitz J, Abudayyeh O, Gootenberg J, Zhang F.

Cold Spring Harb Perspect Biol. 2019 Aug 1;11(8). pii: a035386. doi: 10.1101/cshperspect.a035386. Review.

PMID:
31371352
5.

A cytosine deaminase for programmable single-base RNA editing.

Abudayyeh OO, Gootenberg JS, Franklin B, Koob J, Kellner MJ, Ladha A, Joung J, Kirchgatterer P, Cox DBT, Zhang F.

Science. 2019 Jul 26;365(6451):382-386. doi: 10.1126/science.aax7063. Epub 2019 Jul 11.

PMID:
31296651
6.

Nucleic Acid Detection of Plant Genes Using CRISPR-Cas13.

Abudayyeh OO, Gootenberg JS, Kellner MJ, Zhang F.

CRISPR J. 2019 Jun;2:165-171. doi: 10.1089/crispr.2019.0011.

PMID:
31225754
7.

Structural basis for the promiscuous PAM recognition by Corynebacterium diphtheriae Cas9.

Hirano S, Abudayyeh OO, Gootenberg JS, Horii T, Ishitani R, Hatada I, Zhang F, Nishimasu H, Nureki O.

Nat Commun. 2019 Apr 29;10(1):1968. doi: 10.1038/s41467-019-09741-6.

8.

Chipping in on Diagnostics.

Abudayyeh OO, Gootenberg JS.

CRISPR J. 2019 Apr;2:69-71. doi: 10.1089/crispr.2019.29053.oma. No abstract available.

PMID:
30998093
9.

High-Resolution Structure of Cas13b and Biochemical Characterization of RNA Targeting and Cleavage.

Slaymaker IM, Mesa P, Kellner MJ, Kannan S, Brignole E, Koob J, Feliciano PR, Stella S, Abudayyeh OO, Gootenberg JS, Strecker J, Montoya G, Zhang F.

Cell Rep. 2019 Mar 26;26(13):3741-3751.e5. doi: 10.1016/j.celrep.2019.02.094.

10.

Author Correction: Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.

Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F.

Nat Protoc. 2019 Jul;14(7):2259. doi: 10.1038/s41596-018-0063-0.

PMID:
30349047
11.

Engineered CRISPR-Cas9 nuclease with expanded targeting space.

Nishimasu H, Shi X, Ishiguro S, Gao L, Hirano S, Okazaki S, Noda T, Abudayyeh OO, Gootenberg JS, Mori H, Oura S, Holmes B, Tanaka M, Seki M, Hirano H, Aburatani H, Ishitani R, Ikawa M, Yachie N, Zhang F, Nureki O.

Science. 2018 Sep 21;361(6408):1259-1262. doi: 10.1126/science.aas9129. Epub 2018 Aug 30.

12.

Publisher Correction: Pairwise library screen systematically interrogates Staphylococcus aureus Cas9 specificity in human cells.

Tycko J, Barrera LA, Huston NC, Friedland AE, Wu X, Gootenberg JS, Abudayyeh OO, Myer VE, Wilson CJ, Hsu PD.

Nat Commun. 2018 Aug 28;9(1):3542. doi: 10.1038/s41467-018-06029-z.

13.

Pairwise library screen systematically interrogates Staphylococcus aureus Cas9 specificity in human cells.

Tycko J, Barrera LA, Huston NC, Friedland AE, Wu X, Gootenberg JS, Abudayyeh OO, Myer VE, Wilson CJ, Hsu PD.

Nat Commun. 2018 Jul 27;9(1):2962. doi: 10.1038/s41467-018-05391-2. Erratum in: Nat Commun. 2018 Aug 28;9(1):3542.

14.

Field-deployable viral diagnostics using CRISPR-Cas13.

Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, Kellner MJ, Tan AL, Paul LM, Parham LA, Garcia KF, Barnes KG, Chak B, Mondini A, Nogueira ML, Isern S, Michael SF, Lorenzana I, Yozwiak NL, MacInnis BL, Bosch I, Gehrke L, Zhang F, Sabeti PC.

Science. 2018 Apr 27;360(6387):444-448. doi: 10.1126/science.aas8836.

15.

Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6.

Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F.

Science. 2018 Apr 27;360(6387):439-444. doi: 10.1126/science.aaq0179. Epub 2018 Feb 15.

16.

RNA editing with CRISPR-Cas13.

Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, Zhang F.

Science. 2017 Nov 24;358(6366):1019-1027. doi: 10.1126/science.aaq0180. Epub 2017 Oct 25.

17.

RNA targeting with CRISPR-Cas13.

Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, Cox DBT, Kellner MJ, Regev A, Lander ES, Voytas DF, Ting AY, Zhang F.

Nature. 2017 Oct 12;550(7675):280-284. doi: 10.1038/nature24049. Epub 2017 Oct 4.

18.

Erratum: Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood.

Joung J, Engreitz JM, Konermann S, Abudayyeh OO, Verdine VK, Aguet F, Gootenberg JS, Sanjana NE, Wright JB, Fulco CP, Tseng YY, Yoon CH, Boehm JS, Lander ES, Zhang F.

Nature. 2017 Sep 20;549(7672):418. doi: 10.1038/nature24009.

PMID:
28933431
19.

Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood.

Joung J, Engreitz JM, Konermann S, Abudayyeh OO, Verdine VK, Aguet F, Gootenberg JS, Sanjana NE, Wright JB, Fulco CP, Tseng YY, Yoon CH, Boehm JS, Lander ES, Zhang F.

Nature. 2017 Aug 17;548(7667):343-346. doi: 10.1038/nature23451. Epub 2017 Aug 11. Erratum in: Nature. 2017 Sep 20;549(7672):418.

20.

Nucleic acid detection with CRISPR-Cas13a/C2c2.

Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, Verdine V, Donghia N, Daringer NM, Freije CA, Myhrvold C, Bhattacharyya RP, Livny J, Regev A, Koonin EV, Hung DT, Sabeti PC, Collins JJ, Zhang F.

Science. 2017 Apr 28;356(6336):438-442. doi: 10.1126/science.aam9321. Epub 2017 Apr 13.

21.

Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.

Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F.

Nat Protoc. 2017 Apr;12(4):828-863. doi: 10.1038/nprot.2017.016. Epub 2017 Mar 23. Erratum in: Nat Protoc. 2019 Jul;14(7):2259.

22.

Crystal Structure of the Minimal Cas9 from Campylobacter jejuni Reveals the Molecular Diversity in the CRISPR-Cas9 Systems.

Yamada M, Watanabe Y, Gootenberg JS, Hirano H, Ran FA, Nakane T, Ishitani R, Zhang F, Nishimasu H, Nureki O.

Mol Cell. 2017 Mar 16;65(6):1109-1121.e3. doi: 10.1016/j.molcel.2017.02.007.

23.

Barcode extension for analysis and reconstruction of structures.

Myhrvold C, Baym M, Hanikel N, Ong LL, Gootenberg JS, Yin P.

Nat Commun. 2017 Mar 13;8:14698. doi: 10.1038/ncomms14698.

24.

Erratum: Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array.

Zetsche B, Heidenreich M, Mohanraju P, Fedorova I, Kneppers J, DeGennaro EM, Winblad N, Choudhury SR, Abudayyeh OO, Gootenberg JS, Wu WY, Scott DA, Severinov K, van der Oost J, Zhang F.

Nat Biotechnol. 2017 Feb 8;35(2):178. doi: 10.1038/nbt0217-178b. No abstract available.

PMID:
28178246
25.

Diversity and evolution of class 2 CRISPR-Cas systems.

Shmakov S, Smargon A, Scott D, Cox D, Pyzocha N, Yan W, Abudayyeh OO, Gootenberg JS, Makarova KS, Wolf YI, Severinov K, Zhang F, Koonin EV.

Nat Rev Microbiol. 2017 Mar;15(3):169-182. doi: 10.1038/nrmicro.2016.184. Epub 2017 Jan 23.

26.

Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28.

Smargon AA, Cox DBT, Pyzocha NK, Zheng K, Slaymaker IM, Gootenberg JS, Abudayyeh OA, Essletzbichler P, Shmakov S, Makarova KS, Koonin EV, Zhang F.

Mol Cell. 2017 Feb 16;65(4):618-630.e7. doi: 10.1016/j.molcel.2016.12.023. Epub 2017 Jan 5.

27.

Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array.

Zetsche B, Heidenreich M, Mohanraju P, Fedorova I, Kneppers J, DeGennaro EM, Winblad N, Choudhury SR, Abudayyeh OO, Gootenberg JS, Wu WY, Scott DA, Severinov K, van der Oost J, Zhang F.

Nat Biotechnol. 2017 Jan;35(1):31-34. doi: 10.1038/nbt.3737. Epub 2016 Dec 5. Erratum in: Nat Biotechnol. 2017 Feb 8;35(2):178.

28.

C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector.

Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, Shmakov S, Makarova KS, Semenova E, Minakhin L, Severinov K, Regev A, Lander ES, Koonin EV, Zhang F.

Science. 2016 Aug 5;353(6299):aaf5573. doi: 10.1126/science.aaf5573. Epub 2016 Jun 2.

29.

Corrigendum: Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease.

Dahlman JE, Abudayyeh OO, Joung J, Gootenberg JS, Zhang F, Konermann S.

Nat Biotechnol. 2016 Apr;34(4):441. doi: 10.1038/nbt0416-441a. No abstract available.

PMID:
27054997
30.

Structure and Engineering of Francisella novicida Cas9.

Hirano H, Gootenberg JS, Horii T, Abudayyeh OO, Kimura M, Hsu PD, Nakane T, Ishitani R, Hatada I, Zhang F, Nishimasu H, Nureki O.

Cell. 2016 Feb 25;164(5):950-61. doi: 10.1016/j.cell.2016.01.039. Epub 2016 Feb 11.

31.

Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems.

Shmakov S, Abudayyeh OO, Makarova KS, Wolf YI, Gootenberg JS, Semenova E, Minakhin L, Joung J, Konermann S, Severinov K, Zhang F, Koonin EV.

Mol Cell. 2015 Nov 5;60(3):385-97. doi: 10.1016/j.molcel.2015.10.008. Epub 2015 Oct 22.

32.

Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease.

Dahlman JE, Abudayyeh OO, Joung J, Gootenberg JS, Zhang F, Konermann S.

Nat Biotechnol. 2015 Nov;33(11):1159-61. Erratum in: Nat Biotechnol. 2016 Apr;34(4):441.

33.

Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.

Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F.

Cell. 2015 Oct 22;163(3):759-71. doi: 10.1016/j.cell.2015.09.038. Epub 2015 Sep 25.

34.

In vivo genome editing using Staphylococcus aureus Cas9.

Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F.

Nature. 2015 Apr 9;520(7546):186-91. doi: 10.1038/nature14299. Epub 2015 Apr 1.

35.

Engineered bromodomains to explore the acetylproteome.

Bryson BD, Del Rosario AM, Gootenberg JS, Yaffe MB, White FM.

Proteomics. 2015 May;15(9):1470-5. doi: 10.1002/pmic.201400401. Epub 2015 Mar 5.

36.

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.

Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F.

Nature. 2015 Jan 29;517(7536):583-8. doi: 10.1038/nature14136. Epub 2014 Dec 10.

37.

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F.

Cell. 2013 Sep 12;154(6):1380-9. doi: 10.1016/j.cell.2013.08.021. Epub 2013 Aug 29. Erratum in: Cell. 2013 Oct 10;155(2):479-80.

38.

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

Herndon TM, Demko SG, Jiang X, He K, Gootenberg JE, Cohen MH, Keegan P, Pazdur R.

Oncologist. 2012;17(10):1323-8. doi: 10.1634/theoncologist.2012-0123. Epub 2012 Sep 21.

39.

Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.

Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, Zhao H, Marathe A, Kotch L, Jee J, Wang Y, Zhou L, Adams WM, Jarral V, Pilaro A, Lostritto R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res. 2012 Mar 15;18(6):1496-505. doi: 10.1158/1078-0432.CCR-11-2149. Epub 2012 Jan 26.

40.

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2.

41.

Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.

Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, Lee KY, Weiss KD, Pazdur R.

Clin Cancer Res. 2008 Jun 1;14(11):3242-7. doi: 10.1158/1078-0432.CCR-07-1872.

42.
44.

FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.

Cohen MH, Gootenberg J, Keegan P, Pazdur R.

Oncologist. 2007 Mar;12(3):356-61.

45.

Comparison of intermittent versus continuous infusion of propofol for elective oncology procedures in children.

Klein SM, Hauser GJ, Anderson BD, Shad AT, Gootenberg JE, Dalton HJ, Hertzog JH.

Pediatr Crit Care Med. 2003 Jan;4(1):78-82.

PMID:
12656549
46.

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.

O'Brien KL, Swift AJ, Winkelstein JA, Santosham M, Stover B, Luddy R, Gootenberg JE, Nold JT, Eskenazi A, Snader SJ, Lederman HM.

Pediatrics. 2000 Nov;106(5):965-72.

PMID:
11061761
47.

Prospective evaluation of propofol anesthesia in the pediatric intensive care unit for elective oncology procedures in ambulatory and hospitalized children.

Hertzog JH, Dalton HJ, Anderson BD, Shad AT, Gootenberg JE, Hauser GJ.

Pediatrics. 2000 Oct;106(4):742-7.

PMID:
11015517
48.

Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia. Value of polymerase chain reaction and limitations of flow cytometry.

Kallakury BV, Hartmann DP, Cossman J, Gootenberg JE, Bagg A.

Am J Clin Pathol. 1999 Jun;111(6):759-66.

PMID:
10361511
49.

Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD).

Anderson B, Shad AT, Gootenberg JE, Sandler SG.

Am J Hematol. 1999 Mar;60(3):245-7.

50.

Factor concentrates for the treatment of factor XIII deficiency.

Gootenberg JE.

Curr Opin Hematol. 1998 Nov;5(6):372-5. Review.

PMID:
9814641

Supplemental Content

Loading ...
Support Center